Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that New York State Medicaid wil ...

Accessibility StatementSkip Navigation PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on DrugSorbâ"¢-ATR. On August 20, 2025, the Company announced that it had received a U.S. Food and Drug Administration (FDA) appeal decision regarding the FDA's previous denial letter of the Company's De Novo applicat ...

Accessibility StatementSkip Navigation GALWAY, Ireland, Sept. 15, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes will be fully and unconditionally guaranteed by th ...

Accessibility StatementSkip Navigation Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today The first study implant procedures were performed at The Alfred Hospital in Melbourne, Australia and at The Ohio State University Wexner Medical Center in Columbus, Ohio. The global co-principal investigators for the study are Dr. Atwater and Harriette Van Spall, M.D., Assoc ...

公司产品进展 - 公司新一代单针冷冻消融系统XSense™及冷冻探针获得以色列卫生部医疗器械司（AMAR）的监管批准 该批准涵盖妇科、肿瘤科和普外科等多个适应症 [1] - XSense™系统及其冷冻探针已于2024年年中获得美国食品药品监督管理局（FDA）的监管许可 适应症范围与公司旗舰产品ProSense冷冻消融系统已获FDA批准的范围完全一致 [2] - XSense™在以色列获批的适应症范围与ProSense相同 包括普外科、皮肤科、神经科（含冷冻镇痛）、胸外科、耳鼻喉科、妇科、肿瘤科（含良恶性乳腺肿瘤）、肛肠科和泌尿科 [3] 技术优势与临床价值 - 公司冷冻消融平台技术（含ProSense及XSense™）利用液氮冷冻摧毁肿瘤 具有微创治疗特性 可针对良恶性病变（如乳腺、肾脏、肺部和肝脏肿瘤）形成大面积致死区以实现最大疗效 [4] - 该系统通过加速患者康复、减少疼痛及降低手术风险与并发症 为患者和医疗机构创造价值 其便携式设计和液氮应用特性支持在门诊环境中快速实施乳腺肿瘤手术 [5] 公司战略定位 - 公司专注于开发基于液氮的冷冻消融治疗系统 主要针对乳腺、肾脏、骨骼和肺部肿瘤的摧毁 其微创技术可作为手术切除肿瘤的安全有效替代方案 [6] - 公司认为此次以色列监管批准巩固了其在液氮冷冻消融领域的领导地位 并指出乳腺癌适应症获批将基于日益增长的临床证据加速商业化应用 [3] 业务覆盖范围 - 公司旗舰产品ProSense®系统已在全球范围内销售 覆盖美国、欧洲和亚洲等已获监管批准的市场 [6]

BEIJING, Sept. 15, 2025 (GLOBE NEWSWIRE) -- On September 3, 2025, the "2025 New Technology Symposium on Retinal Peripheral Vision and the First VPR Clinical Academic Exchange Conference" was held in Hangzhou, hosted by Chinese Association of Pathophysiology and Ophthalmology Professional Committee of Chinese Association of Pathophysiology, and organized by Beijing NineStars Intelligent Medical Equipment Co., ltd. The conference focused on the launch and clinical application of wide-field retinal peripheral ...

Accessibility StatementSkip Navigation It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.virtualinvestorconferences.com. Kelyniam has both sales momentum and additional product line enhancements to present to the current market. Surgeons who like the osteointegrative benefits of implants can find similar or better results with the CustomizedBon ...

活动概况 - 活动紧扣服贸会"数智领航、服贸焕新"主题 全面呈现北京市首台（套）重大技术装备领域的新成果、关键技术突破与产业贡献 [1][4] - 活动由北京市发展改革委、北京市商务局主办 于9月12日上午在北京首钢园举办 北京市发展改革委党组副书记、副主任林剑华出席 市级相关部门、11个区发展改革委及北京经济技术开发区管委会相关负责人、行业专家和首台（套）企业代表共80余人参加 [2] 主旨报告 - 机械工业仪器仪表综合技术经济研究所所长欧阳劲松与中国科学院科技战略咨询研究院研究员穆荣平应邀出席 分别围绕"装备数字化发展"和"未来产业的政策创新"两大前沿议题进行解读 从战略高度、政策层面与创新实践等多维度展开分析 [5] 政策支持与企业认证 - 北京市发展改革委对首台（套）综合性政策作深入解读 林剑华会同市级相关部门、各区发改委负责人共同为2025年第二、三批首台（套）企业颁发证书 [8] - 政策宣讲与认证表彰相结合 体现北京市以务实举措推动科技创新与产业应用深度融合的决心 [17] 项目签约与合作 - 北京机器人融资租赁股份有限公司与北京术锐机器人股份有限公司、北京唯迈医疗科技股份有限公司2家单位达成医用机器人租赁项目合作并完成现场签约 [18] - 各方共同推动华科精准（北京）医疗科技有限公司神经外科手术导航定位系统智能化改造提升项目及北京易加三维科技有限公司金属3D打印扩能提升项目加速落地 [20] 创新产品展示 - 北京玻色量子科技有限公司展示1000量子比特云服务 北京极光星通科技有限公司展示星间激光通信终端 北京万东医疗科技股份有限公司展示全球首发第三代无液氦磁共振 通号城市轨道交通技术有限公司展示深度自主化CBTC系统 [22] - 组织60余家首台（套）企业参与服贸会示范案例展示、电信计算机和健康卫生服务专题展及线上平台展示 [23] 未来规划 - 北京市发展改革委将牢牢把握首都城市战略定位 紧紧围绕北京国际科技创新中心建设使命 继续突出研发创新、中试检测、示范应用全链条全服务 进一步完善首台（套）现行政策 [26] - 推动更多创新成果转化为现实生产力 加速高端装备、未来产业升级 为北京经济高质量发展注入更强劲动能 [27]

Resmed CDI (Netwealth Group Ltd (RMD share price in focusThe ASX:RMD ) share price has risen 11.6% since the start of 2025. The ASX:NWL ) share price is about 57.7% above its 52-week low.ResMed is a medical equipment company based in San Diego, California, but originally founded in Australia by Peter Farrell. The company provides cloud-connectable continuous positive airway pressure, or CPAP, machines for the treatment of obstructive sleep apnea (OSA). ResMed shares are listed both on the NYSE and the ASX. ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is one of the stocks Jim Cramer shared insights on. Inquiring about the stock during the lightning round, a caller expressed that their son and grandson use products made by the company. Here’s what Cramer had to say in response: “Alright, so… this is one of those, this is really difficult because I want to go with them, and the reason I want to go with them is they’re young. If they made a mistake, they got their whole life ahead of them. They’ve had the personal ...